Share on StockTwits

Mylan (NYSE:MYL) Director Neil Dimick sold 5,813 shares of the stock on the open market in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $43.15, for a total transaction of $250,830.95. Following the transaction, the director now directly owns 32,136 shares of the company’s stock, valued at approximately $1,386,668. The sale was disclosed in a filing with the SEC, which is available at this link.

Mylan (NYSE:MYL) traded up 0.33% during mid-day trading on Friday, hitting $42.72. 1,876,910 shares of the company’s stock traded hands. Mylan has a one year low of $27.38 and a one year high of $44.73. The stock has a 50-day moving average of $42.85 and a 200-day moving average of $37.74. The company has a market cap of $16.356 billion and a P/E ratio of 27.99.

Mylan (NYSE:MYL) last announced its earnings results on Thursday, October 31st. The company reported $0.82 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.79 by $0.03. The company had revenue of $1.77 billion for the quarter, compared to the consensus estimate of $1.84 billion. During the same quarter in the previous year, the company posted $0.83 earnings per share. The company’s revenue for the quarter was down 1.9% on a year-over-year basis.

Several analysts have recently commented on the stock. Analysts at Leerink Swann raised their price target on shares of Mylan to $50.00 in a research note to investors on Monday, November 25th. Separately, analysts at Zacks downgraded shares of Mylan from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, November 20th. They now have a $44.00 price target on the stock. Finally, analysts at Zacks reiterated an “outperform” rating on shares of Mylan in a research note to investors on Friday, November 1st. They now have a $45.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $39.35.

Mylan Inc (NYSE:MYL) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.